10:25 AM EDT, 04/30/2025 (MT Newswires) -- Teleflex ( TFX ) said Wednesday that the US Food and Drug Administration gave 501(k) clearance for expanded use of the QuikClot Control+ hemostatic device to include all grades of internal and external bleeding.

The expanded clearance covers procedures in general surgery, gynecologic surgery, orthopedic surgery and other areas, the company added.

The expanded use will add more than $150 million to the company's serviceable addressable market in the US, according to Teleflex ( TFX ).

Shares of the company were down 3% in recent trading.

Price: 134.33, Change: -3.89, Percent Change: -2.81